Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



The Weaknesses in Sanofi's Diabetes Franchise

French pharmaceutical giant Sanofi (NYSE: SNY  ) is currently the leader in the long-acting insulin space. Its product Lantus is used by diabetes patients around the world, and it's currently the company's best selling drug. However, what are the challenges up ahead for Sanofi? Will Lantus' multibillion-dollar sales continue in perpetuity? What about Sanofi's other insulin drug Apidra -- is this product a weakness in the company's diabetes franchise?

In the following video, health care analyst Max Macaluso discusses these topics and probes Sanofi's strengths and weaknesses.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 09, 2013, at 6:58 PM, cdb5556 wrote:

    Sanofi has had lousy R and D. (Accomplia, Ketek anyone?). They have lost Plavix, and are about to lose Lantus. That Lantus business is maxed out..most everyone that could be put on it are already using it. Hard to grow a product that is this much of a market leader and this old. Meanwhile, CEO Viebacher is re-making this old line "big pharma" company into a generic-vaccine-boutique drug maker. Genzyme purchase (the boutique part of the re-make) has some potential, but the rest is just commodity based. Sorry, Sanofi is too risky for me,.

  • Report this Comment On April 10, 2013, at 12:47 AM, fanfool3 wrote:

    Sanofi does have patent expansion until 2015 for Lantus so a small delay maybe but neverthless another 6 months of exclusivity. Sanofi faces competition from arch rival Lilly who is making a biosimilar version of glargine. The Mylan-Biocon is still further ahead and will face regulatory hurdles most probably. Lilly is imminent. Apidra has no chance of surviving with Novo and Lilly gaining market share.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2354359, ~/Articles/ArticleHandler.aspx, 9/25/2016 6:53:21 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:02 PM
SNY $38.35 Down -0.22 -0.57%
Sanofi CAPS Rating: *****